« Return to News | CROs/Service Providers

ICON Opens Office in Philippines

Tuesday, April 6, 2010 06:59 AM

Dublin, Ireland-based contract research organization (CRO) ICON opened an office in Manila, Philippines, to support the company’s growth in Asia-Pacific.

ICON has more than 800 employees in Asia-Pac countries and has operated in the region for 13 years.  CEO Peter Gray called the region a “key market” for ICON, which has a presence in 14 Asia-Pacific countries, including Australia, China, Hong Kong, India, Indonesia, Japan, Korea, Malaysia, New Zealand, Philippines, Singapore, Taiwan, Thailand and Vietnam.

“Philippines’ large population, coupled with the country’s well-established network of hospitals, physicians and investigators has made it an attractive location for our clients, and one which we have supported for a number of years through home-based employees,” Gray said. “Investing in local support and infrastructure through the office in Manila will ensure that we can support future client demand as they increasingly look to include Asia in their drug development programs.”

The company also has two central laboratories in Singapore and Bangalore, India.

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.